NCT01165346 2026-03-13
CKNO-HEP
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
71 trialsNCT02648282 2026-03-13
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04975516 2026-03-03
Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Terminated
NCT06218420 2026-03-03
TRANSRAD-01
Assistance Publique - Hôpitaux de Paris
Phase 2 Recruiting
NCT06603818 2026-02-19
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT07126158 2026-01-05
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT07297004 2025-12-22
Stereotactic Body Radiation Therapy for Unresectable Locally Recurrent Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting
NCT02713269 2025-10-30
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07173387 2025-09-15
RAD-NALIRIFOX
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT06843551 2025-08-14
EMPIRE
University of Miami
Phase 2 Recruiting
NCT03316872 2025-07-25
Study of Pembrolizumab and Radiotherapy in Liver Cancer
University Health Network, Toronto
Phase 2 Terminated
NCT01781728 2025-07-20
Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05379972 2025-07-16
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
University of Colorado, Denver
Phase 2 Active not recruiting
NCT06356584 2025-06-26
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07030140 2025-06-22
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT07007728 2025-06-06
Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06991491 2025-05-28
Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)
West China Hospital
Phase 2 Not yet recruiting
NCT03073785 2025-05-25
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
University of Nebraska
Phase 2 Active not recruiting
NCT05375708 2025-03-28
SIRIUS
UMC Utrecht
Phase 2 Suspended
NCT03161379 2025-02-03
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT06767007 2025-01-22
SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting
NCT06766643 2025-01-09
Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT02185443 2024-12-09
Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases
University of Sao Paulo
Phase 2 Recruiting
NCT01539824 2024-11-25
A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer
Immodulon Therapeutics Ltd
Phase 2 Completed
NCT06313190 2024-11-18
HSBRT2402
Sun Yat-sen University
Phase 2 Recruiting
NCT06664996 2024-10-30
Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT
West China Hospital
Phase 2 Recruiting
NCT04899908 2024-10-24
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06592612 2024-09-19
Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06573398 2024-08-27
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06422156 2024-05-20
Nim-PC-28
Peking University Third Hospital
Phase 2 Not yet recruiting
NCT06261125 2024-03-12
HSBRT2401
Sun Yat-sen University
Phase 2 Recruiting
NCT02128100 2024-03-05
BCC-RAD-13
University of Louisville
Phase 2 Completed
NCT02182687 2024-03-05
SBRTvsTACE
Lahey Clinic
Phase 2 Completed
NCT05626569 2024-01-03
Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC
Sun Yat-sen University
Phase 2 Unknown
NCT01959672 2023-10-10
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
University of Nebraska
Phase 2 Completed
NCT03777462 2023-09-01
BRPCNCC-1
Changhai Hospital
Phase 2 Unknown
NCT05783076 2023-08-30
SBRT Plus vNKT for Pancreatic Cancer
Changhai Hospital
Phase 2 Unknown
NCT06009029 2023-08-24
SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)
Peking University Third Hospital
Phase 2 Not yet recruiting
NCT02513199 2023-06-18
Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT05157451 2023-03-23
Y-90 Versus SBRT for Inoperable HCC
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT05747716 2023-02-28
SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT05679583 2023-01-11
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
Yonsei University
Phase 2 Recruiting
NCT03099265 2022-10-27
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Yale University
Phase 2 Terminated
NCT03158779 2022-09-15
Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer
Istituto Clinico Humanitas
Phase 2 Completed
NCT04924179 2022-08-17
Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC
Huazhong University of Science and Technology
Phase 2 Unknown
NCT03199144 2022-06-23
CKPancreas
Centre Francois Baclesse, Luxembourg
Phase 2 Withdrawn
NCT01360593 2022-03-08
Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
University of Pittsburgh
Phase 2 Completed
NCT04089150 2021-10-22
MASTERPLAN
Australasian Gastro-Intestinal Trials Group
Phase 2 Unknown
NCT00914355 2021-10-06
Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma (COLD 2)
University Health Network, Toronto
Phase 2 Completed
NCT04913480 2021-06-04
SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
The University of Hong Kong
Phase 2 Unknown